Datavault AI expands PharmacyChain blockchain licensing deal with DataMeds AI to broader healthcare uses
DVLT•PharmacyChain licensing deal expands to broader healthcare uses
Datavault AI expanded its PharmacyChain technology licensing deal with DataMeds AI to cover unencumbered commercial healthcare, healthspan, wellness applications.
Amended terms shift consideration to common shares equal to about 19.9% of DataMeds stock at closing, replacing preferred shares for tax optimization.
Closing remains tied to DataMeds completing related acquisitions, including two QOLPOM IP portfolios from EOS Technology Holdings.
The partnership targets patient-controlled healthcare data monetization, credentialing, blockchain-based data transactions, and real-world asset tokenization across pharmacy, medical, lab, and wearables settings.
